Iridex
IRIXIridex Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems for treating sight-threatening eye conditions.
Table of contents
Earnings
Next report
Aug 18, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Iridex Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems for treating sight-threatening eye conditions. The company's core value proposition centers on its proprietary MicroPulse and Endpoint Management technologies, which provide tissue-sparing, subvisible laser therapy for glaucoma and retinal diseases. By offering a safer clinical profile compared to traditional high-energy continuous-wave lasers, Iridex enables physicians to stabilize vision while minimizing collateral tissue damage.
A specialized provider of tissue-sparing ophthalmic lasers, leveraging proprietary microsecond-pulse technology to compete against traditional high-energy photocoagulation systems.
Questions, answered.
- What is Iridex's market cap?
- Iridex (IRIX) has a market capitalization of $15.5M and trades on NASDAQ.
- Who are Iridex's competitors?
- Iridex's key competitors include Bausch + Lomb, Harrow, Inc. Common Stock, LENSAR, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Iridex partner with?
- Iridex's notable partners include Topcon Corporation, Lumenis, Alcon.
- Where is Iridex headquartered?
- Iridex is headquartered in United States of America and employs approximately 139 people. It has been publicly traded since 1996.